Rethinking Clinical Trial Country Prioritization<\/a>“).<\/p>\n\n\n\nAs the study points out, Europe has lost dominance in clinical trials of pharmaceuticals over the past decade, to the US and the exponential growth seen in China.<\/p>\n\n\n\n
Internationally, clinical drug trials have increased over the past 10 years by 38%, however, Europe’s share fell to 12% in 2023 from 22% in 2013. In the same 10 years, clinical trials in China increased to 29% last year, from 8% in 2013, making Asia a hub for conducting clinical trials. This, in fact, at the expense of established clinical study centers in Europe and North America, where the number of studies has decreased by 10% in the last decade, both in Europe and in North America.<\/p>\n\n\n\n
But the study warns of a future major downturn in the field of clinical trials in Europe, due to a significant reduction in phase I clinical trials. During phase I, the safety and appropriate doses of the future drug are evaluated, and conducted in a small number of appropriately selected patients . The reduction in the number of phase I studies could lead to a further reduction in clinical trials of new drug candidates in Europe, as the knowledge and equipment developed at this stage support later phases, the report points out.<\/p>\n\n\n\n
In Europe, oncology clinical studies make up at least 25% of clinical studies conducted in the region as a whole, followed by cardiovascular and rheumatology clinical studies with approximately 10% for each area.<\/p>\n\n\n\n
As far as pediatric drugs are concerned, clinical studies for them have decreased in Europe by 7% to 75 studies in 2023, from 142 in 2012, when an increase of 4% was observed internationally.<\/p>\n\n\n\n
However, the report finds that three countries \u2013 Greece, Portugal and Slovakia \u2013 have bucked the overall downward trend seen in Europe, with Spain proving to be the leader in clinical trials in Europe, ranking 4th internationally after USA, China and Japan. Industry investment in clinical studies in Spain reached \u20ac834 million in 2022, up from \u20ac479 million in 2012.<\/p>\n\n\n\n
New regulation<\/strong><\/p>\n\n\n\nThe report attributes the fact of the decrease in Europe’s market share to the increase in availability in third countries, to the effects of the pandemic on the health systems and economies of the European states, but also to the new EU regulations. which come into force.<\/p>\n\n\n\n
As early as January 2023, the EU Clinical Trials Regulation came into force, aiming to ensure that the EU provides an attractive and enabling environment for conducting large-scale clinical research, maintaining high standards of transparency and safety for those involved in clinical trials. studies.<\/p>\n\n\n\n
But the IQVIA study points out that the intention falls short of the target, noting that “at best, Europe has held but not improved its position”.<\/p>\n\n\n\n
Delays<\/strong><\/p>\n\n\n\nOther factors influencing the decline in clinical trials in Europe are longer clinical trial timelines and patient recruitment, which moves more slowly than in the U.S., the report notes, noting that oncology clinical trials last Europe 37 months, versus 34 in the US, for rare diseases 32 months versus 26 in the US, and for infections 21 months, versus 17 in the US.<\/p>\n","protected":false},"excerpt":{"rendered":"
Europe has lagged behind the US and Asia in clinical trials to develop new drugs over the past decade, as drugmakers seek the speed…<\/p>\n","protected":false},"author":1,"featured_media":21267,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,2993,2958],"tags":[6164,3870,25,470,4053],"class_list":["post-21265","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","category-life","category-medical","tag-clinical-studies","tag-drugs","tag-eu","tag-europe","tag-studies"],"_links":{"self":[{"href":"https:\/\/www.liberalglobe.com\/index.php?rest_route=\/wp\/v2\/posts\/21265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.liberalglobe.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.liberalglobe.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.liberalglobe.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.liberalglobe.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21265"}],"version-history":[{"count":1,"href":"https:\/\/www.liberalglobe.com\/index.php?rest_route=\/wp\/v2\/posts\/21265\/revisions"}],"predecessor-version":[{"id":21268,"href":"https:\/\/www.liberalglobe.com\/index.php?rest_route=\/wp\/v2\/posts\/21265\/revisions\/21268"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.liberalglobe.com\/index.php?rest_route=\/wp\/v2\/media\/21267"}],"wp:attachment":[{"href":"https:\/\/www.liberalglobe.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.liberalglobe.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.liberalglobe.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"https:\/\/www.liberalglobe.com\/wp-content\/uploads\/2024\/11\/image-1-1024x529.png\")